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ABSTRACT: 
BACKGROUND: 
Initiating twice weekly HD (2XHD), in patients who retain significant RKF, may have benefits. We 
aimed to determine differences between patients initiated on twice- and thrice-weekly 
regimes, with respect to loss of kidney function, survival, and other safety parameters.  
METHODS: 
We conducted a single-centre retrospective study of patients initiating dialysis with a residual 
urea clearance (KRU) of 3 ml/min or more, over a twenty year period. Patients who had 
dialysed twice-weekly for 3 months or more during the 12 months following initiation (2XHD) 
were identified for comparison with those dialysed thrice-weekly (3XHD).    
RESULTS: 
The 2XHD group consisted of 154 patients, and the 3XHD group 411. 2XHD patients were 
younger (59 ± 15 vs 62 ± 15: p = 0.014) and weighed less (70 ± 16 vs 80 ± 18: p <0.001). More 
were female (34% vs 27%: p= 0.004). Fewer had diabetes (25% vs 34%: p = 0.04) and peripheral 
vascular disease (13% vs 23%: p = 0.008). Baseline KRU was similar (5.3 ± 2.4 vs 5.1 ± 2.8: p = 
0.507) but loss KRU slower in the 2XHD group. In a mixed effects model correcting for between 
group differences in comorbidities and demographics, 3XHD was associated with increased rate 
of loss of KRU and separation of KRU. In separate mixed effects models, group (2XHD v 3XHD) 
was not associated with differences in serum potassium or phosphate and the groups did not 
differ with respect to total standard Kt/V. Survival, adjusted for age, gender, weight, baseline 
KRU, and comorbidity (prevalence of diabetes, cardiac disease, peripheral vascular disease and 
malignancy) was greater in the 2XHD group (Hazard ratio 0.755: p = 0.044). In sub-analyses the 
survival benefit was confined to women, and those of less than median bodyweight.  
CONCLUSION: 
Twice weekly dialysis initiation as part of an incremental programme with regular monthly 
monitoring of KRU was safe and associated with a reduced rate of loss of residual kidney 
function early after dialysis initiation and improved survival. Randomised controlled trials of this 
approach are indicated.  
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INTRODUCTION: 
 
Twice weekly haemodialysis (2XHD) was a common modality in the early days of dialysis, 
usually involving long sessions often exceeding 12 hours [1].  This regime subsequently gave 
way to adoption of thrice weekly schedules (3XHD) of around four hours per session which is 
still regarded as standard. Set against this, 2XHD treatments came to be regarded as suboptimal 
and associated with rationing of resources [2]. Indeed 2XHD treatments remain common in 
developing countries, conditioned by resource constraints [3-5].  The growing awareness of the 
importance of residual kidney function (RKF) in dialysis outcomes, has increased interest in 
incremental dialysis initiation and in 2XHD initiation as part of this [6-9].  
 
Most patients initiating dialysis retain small but significant amounts of RKF which can persist at 
levels associated with outcome benefits even several years of treatment [6, 7, 10-13]. This 
preservation of RKF was previously thought to be confined to peritoneal dialysis but it is now 
apparent that it also extends to the HD setting [14, 15]. Benefits of preserved RKF include 
improved small and middle molecule clearance, better health- related quality of life, reduced 
erythropoietin requirements, reduced ultrafiltration requirements, and improved control of 
blood pressure, nutritional status and phosphate levels [10, 16-19]. Furthermore, RKF improves 
survival  [6, 10, 20, 21]. The presence of levels of renal urea clearance (KRU) as low as 
1ml/min/1.73m2 has been associated with a significantly reduced mortality risk [10].  Dialysis 
strategies that protect RKF may therefore be beneficial. Observational studies have suggested 
that patients commencing 2XHD may have a slower rate of decline of RKF [22-24]. Incremental 
dialysis, whereby dialysis dose is individualized according to the prevailing level of RKF [8], 
might protect against RKF loss by reducing dialysis intensity for patients who retain significant 
RKF. HD dose is increased successively as RKF declines.  
 
Our centre has practiced incremental dialysis over 25 years with careful and regular monitoring 
of RKF. In this paper we present our experience of outcomes in patients who started dialysis on 
2XHD schedules as part of an incremental HD programme, and compare these to outcomes in 
4 
 
patients with similar levels of kidney function who commenced on 3XHD schedules. The main 
aim of the study was to determine whether there were differences between patients in the 
2XHD and 3XHD groups with respect to rate of loss of RKF and other key indicators of dialysis 
safety including, anaemia control, potassium control and survival. 
 
 
METHODS: 
 
Patients 
We retrospectively studied patients who initiated HD at the Lister Renal unit with a residual 
urea clearance (KRU) of 3ml/min or more over the 20 year period between from 1989 (n = 565). 
All patients had a potential follow up period of at least 5 years following HD initiation. We 
excluded patients who had HD for <3 months, those transferring from other centres already on 
dialysis, those transferring from peritoneal dialysis to HD, those returning to dialysis following a 
failed renal transplant and those who initiated HD in our unit and were transferred out to a 
different unit.  
  
Definition of groups for comparison 
The study population was divided into two groups: those who had initiated HD twice weekly for 
more than 3 months during the first 12 months of HD (2XHD group) and all other patients who 
had initiated treatment thrice weekly or received twice weekly treatment for only a brief period 
of <3 months (3XHD group). Patients in the 2XHD group who subsequently had their dialysis 
intensity increased to thrice weekly were considered part of the 2XHD group. We excluded 
from the 2XHD group patients who on review of the case notes had undergone twice-weekly 
treatment for palliative purposes or during recovery from acute kidney injury. 
 
Haemodialysis Programme 
All patients were treated exclusively using high-flux membranes with either high-flux HD or 
haemodiafiltration. Ultrapure water was used for dialysis and was regularly monitored to 
ensure tight bacteriological standards. Bicarbonate was used as the buffer. Dialysis fluid 
microbiological standards were <0.1 cfu/ml and<0.03 EU/ml. 
5 
 
  
Dialysis adequacy and RKF 
HD was delivered using an incremental dialysis regime whereby regardless of dialysis frequency 
(twice or thrice weekly) patients had the same total target urea clearance. This was achieved by 
utilizing a total two-pool Kt/V urea target for patients comprised of dialyser clearance 
(Kt/Vdialysis) and RKF equivalent clearance (Kt/Vrenal).  Kt/Vrenal was calculated using the method 
described by Gotch et al [10] which converts urea clearance to an equivalent per-session Kt/V. 
This method aims to take into account the higher efficiency of urea removal by RKF compared 
to that of the dialyser.  The approximate equivalent minimum target total two pool Kt/V 
(Kt/Vtotal) used for both groups, equates to 2.0 per session for 2XHD patients and 1.2 per session 
for 3XHD.  
 
The following formulae describe the method used to calculate Kt/Vtotal: 
 
Kt/Vtotal = Kt/Vrenal + Kt/Vdialysis  
 
Kt/Vrenal = (KrU∗ f)/V 
 
where KrU is urea clearance (ml/min)f = 9500 for twice weekly HD or f = 5500 for thrice weekly 
and V is Watson volume (ml). 
 
In order to calculate Kt/Vrenal, the dialysis unit protocol measured RKF monthly using an inter-
dialytic urine collection and the mean inter-dialytic urea concentration (the mean of the pre- 
and post-dialytic serum urea concentrations, with post dialysis urea corrected for rebound). 
Urine collections were performed over the inter-dialytic period from Monday to Wednesday or 
Tuesday to Thursday depending on the dialysis schedule for thrice weekly patients and from 
Friday to Monday or Saturday to Tuesday for twice weekly patients. 
 
 The following equation was used to calculate KRU: 
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KrU (ml/min) = 2(UID · VID)/tID (Cpost +Cpre) 
 
In this equation, UID was urinary urea concentration (mmol/ml) in the inter-dialytic urine 
collection; VID was the urine collection volume (ml); tID was the duration of the inter-dialytic 
urine collection (mins); Cpost was post-dialysis serum urea (mmol/l) and Cpre was pre-dialysis 
serum urea (mmol/l).  
 
 Patients with urine output <100ml/day for two or more consecutive monthly collections were 
classified as anuric. All patients passing >100 ml urine/ day were routinely requested to perform 
monthly inter-dialytic urine collections to calculate Kt/Vrenal. Patients failing to provide urine 
collections for ≥3 months were assumed to be anuric to prevent under-dialysis. 
 
Baseline characteristics 
Baseline characteristics were collected for all patients which included age, height, pre-dialysis 
weight at dialysis initiation, sex, cause of underlying renal disease, and routine haematological 
and biochemical data. Comorbidity data were defined at dialysis initiation including diabetic 
status, cardiac disease, peripheral vascular disease, and malignancy.  
 
Outcome data 
The outcome data were collected at the closest time point ±1 month to 0, 3, 6, 12, 24, 36, 48 
and 60 months after dialysis initiation. Parameters including  KRU, pre-dialysis weight, 
frequency of HD, serum potassium levels, serum phosphate levels, haemoglobin levels, serum 
albumin level, Erythropoiesis-stimulating agent weekly dose, and Erythropoietin resistance 
index (ERI). Estimates of total standard Kt/V as combined dialysis StdKt/V and renal StdKt/V  
[25] were also collected at each of these time points. Data were not collected after date of 
transplantation, transfer to other dialysis modality or transfer to another dialysis centre. 
 
Survival 
Patient survival was measured from the date of HD initiation to death. 
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Statistical analysis 
Statistical analysis was performed with IBM ®SPSS®Statistics version 24 and STATA. 
To determine if there was a difference in rate of decline of KRU between the 2XHD and 3XHD 
groups, a mixed effects model was fitted which allowed for within-individual variation in 
baseline KRU (random intercept). The model was fitted with restricted cubic splines, so that 
KRU could be modelled flexibly. Knots were placed at 12 and 24 month time points to match 
the changes in slopes seen in raw data. Group and time were included as  fixed factors in the 
model, and also a group-time interaction parameter was included as a fixed effect. Differences 
in groups were controlled for by including age, sex, baseline weight and comorbidities as fixed 
effects. 
 
The following outcome parameters were compared between 2XHD and 3XHD groups also using 
mixed effect models: potassium, phosphate, haemoglobin, erythropoitetin dose, erythropoietin 
resistance index, ultrafiltration volume  and total Standard Kt/V (residual renal plus dialysis). 
Mixed model effects were fitted which allowed for within-individual variation in baseline KRU 
(random intercept), and included group (2XHD or 3XHD) and time as fixed effects and 
additionally included the interaction of group and time as a fixed effect. A quadratic term for 
time was assessed as a fixed effect and found to add to the fit of the model for potassium, 
haemoglobin and erythropoietin resistance index. A random slope was considered, allowing for 
rate of change of each outcome to vary over time by patient and was found to improve model 
fit for all models except phosphate. 
 
Survival was compared between the 2XHD and 3XHD groups using Kaplan-Meier univariate 
analysis. In order to correct for the effect of confounding variables on survival, we used a Cox 
proportional hazards model comparing survival between the 2XHD and 3XHD groups. 
Confounding variables included in the model were age, sex, baseline weight, baseline 
comorbidity (diabetes, cardiac disease, peripheral vascular disease, malignancy), and baseline 
KRU (the maximum KRU recorded in the first 3 months of treatment). In survival analyses 
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patients were censored for transplantation, transfer to another dialysis modality or another 
dialysis centre. 
 
RESULTS: 
 
Baseline characteristics 
A total of 583 patients initiated HD with KRU of 3 ml/min. Four hundred and eleven patients 
initiated three times a week dialysis (3XHD group), and 172 initiated twice a week dialysis. Of 
these, 18 patients were excluded comprising 6 receiving palliative twice-weekly HD and 12 
receiving HD twice-weekly while recovering from acute kidney injury. The 2XHD group 
therefore comprised 154 patients. Median start year commencing HD was 1998 versus 2001 in 
2XHD and 3XHD groups respectively. For patients in the 2XHD group, median duration on twice 
weekly dialysis was 12 months. 
 
Baseline data for the 2XHD and 3XHD groups are shown in Table 1. Patients in the 3XHD group 
were significantly older and heavier. Fewer in this group were female. More had diabetes, and 
peripheral vascular disease. There were no differences between the groups with respect to the 
level of baseline renal function, baseline haemoglobin levels and the prevalence of malignancy. 
There were equivocal differences with respect to the prevalence of cardiac disease and the 
spectrum of primary renal disease between the two groups.  
 
Duration of twice weekly treatment 
The median time spent on twice-weekly HD was 9 (IQR 12) months. The time ranged from 3 to 
54 months. 
 
 
 
Comparison of rate of deterioration of KRU 
The decline of KRU over the five years post initiation is shown in Figure 1.  Missing KRU data 
were present in 10.5% of potential datapoints. Though KRU at baseline was similar in each 
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group, there were significant differences between groups at all other time points up to 60 
months (Figure 1). 
In the mixed effects model to determine the effect of group (2XHD or 3XHD ) on KRU,  
restricted cubic splines and knots were employed and the optimum model included knots at 12 
and 24 months (see Table 2). There was evidence to include time as a random effect in the 
model (Log Likelihood Ratio test[LLR] 50.86, p<0.001) but the resulting standard deviation was 
small (0.03) indicating that there was little variation over time, therefore this was not included 
in the model for parsimony. Primary renal disease was not included in the model since it did not 
contribute significantly to the model (LLR 6.33, p=0.39). Year from commencing dialysis also did 
not contribute significantly to the model. Factors in the model are shown in Table 2 and 
significant factors predicting KRU included group (2XHD v 3XHD),time, the group-time 
interaction,  sex, weight and presence of heart disease. Use of splines resulted in three time 
parameters and three group-time interaction parameters. 
The modelled effect of a patient being in the 2XHD group (compared to 3XHD group) is shown 
in Figure 2. There is increasing difference in KRU between groups to 12 months. From 12 to 24 
months the difference in KRU between groups decreases as the 3XHD group levels out while 
the 2XHD groups’s KRU continues to decrease. From 36-60 month the difference reduces but 
with KRU in the 2XHD group remaining around 1ml/min higher than in the 3XHD group. Model 
performance shown in Figure 3 which shows good agreement between observed and fitted 
data. 
 
Comparison of haematological, biochemical, dialysis adequacy and volume control 
parameters 
Raw data for haemoblobin, erythropoietin dose and Erythropoietin Resistance Index in 2XHD 
and 3XHD groups are shown in Figure 4. Raw dialysis adequacy data using Standard Kt/V are 
shown in Figure 5 which includes Standard Kt/V (Total) plus its components (Standard Kt/V 
Renal and Standard Kt/V Dialysis). Ultrafiltration volume data are shown in Figure 6. 
Summaries of mixed effects models comparing potassium, phosphate, haemoglobin, 
erythropoietin dose, Erythropoietin Resistance Index, ultrafiltration volume and Total Standard 
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Kt/V are shown Table 3. All outcomes were affected by time, other than Total Standard Kt/V. 
There was a significant difference between 2XHD and 3XHD groups for ESA dose, erythropoietin 
resistance index and ultrafiltration volume (lower in 2XHD groups, see Table 3). He interaction 
term Group*Time to determine the difference between 2XHD group and 3XHD group over time 
was significant for erythropoietin dose only, meaning that there was no evidence that the rate 
of change of the other outcomes differed between groups. 
These models with time as a random effect suggest the rate of change of each outcome varies 
by patient. Erythropoietin dose and ultrafiltration volume had large estimated standard 
deviations suggesting that the rate of change varies widely across patients, whereas other 
models showed small differences among patients (see Table 3, Random Effects SD Time) .  
Similarly, for erythropoietin dose,  ultrafiltration volume and haemoglobin the estimated 
intercept standard deviations were high suggesting a difference in levels of these outcomes 
across patients at all times. The residual standard deviation for the models represent the 
residual population standard deviation not explained by the model. This was relatively high for 
erythropoietin dose and ultrafiltration volume suggesting that other factors are affecting these 
not accounted for in the model. 
 
 
 
Survival 
Unadjusted survival was significantly higher for patients in the 2XHD group (median survival 5.6 
years vs 4.6 years: p = 0.003). The Cox regression model depicted in Table 4, demonstrates a  
benefit  for twice- vs thrice-weekly dialysis on survival - adjusted for age, sex, baseline body 
weight, baseline comorbidity (diabetes, peripheral vascular disease and malignancy), and 
residual kidney function (maximum urea clearance in first 3 months). Twice- weekly treatment 
was associated with a reduced adjusted mortality risk of 24% (p = 0.044), corresponding to an 
adjusted median survival of 6.1 vs 5.0 years.  
 
When the analysis was restricted to women it was apparent that the adjusted survival 
advantage of 2XHD was greater – the reduced mortality risk was 44% (p = 0.038) corresponding 
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to an adjusted medial survival of 7.8 vs 4.8 years. There was no survival advantage of twice 
weekly dialysis in men (Table 3).  Restricting the analysis to patients with body weight less than 
the median also showed a benefit for2XHD treatment in this group. Twice-weekly treatment 
was associated with a reduced adjusted mortality risk of 39% (p = 0.006) corresponding to an 
adjusted median survival of 6.8 vs 4.3 years. There was no survival advantage for heavier 
patients (Table 3).  
 
 
CONCLUSION 
 
We found that the rate of decline of KRU in patients initiating incremental HD with KRU of 3 
ml/min or more was significantly slower in patients who received 2XHD compared to 3XHD, 
with increasing separation of KRU up to 12 months, and after this time KRU remained higher in 
those on 2XHD even up to 5 years. There were no differences between the groups in a mixed 
effects model with respect to total standard Kt/V though a greater proportion of the total dose 
was delivered by RKF in the 2XHD group who correspondingly received less dialysis at all points 
up to 36 months. 2XHD was associated with lower ultrafiltration volume even after correcting 
for baseline KRU in a mixed effect model. There were no detrimental effects on anaemia 
management. Haemoglobin levels similar in both groups, and erythropoietin doses and 
erythropoietin resistance index were actually lower in the 2XHD. Likewise there were no 
significant differences between groups in potassium and phosphate levels.  Survival was not 
adversely affected by receiving 2XHD treatment, and in fact we found slightly better unadjusted 
and adjusted survival in those receiving 2XHD treatments, though in subgroup analysis the 
effect seemed largely confined to women and those with lower body weight. Overall these data 
provide reassurance regarding the safety of twice weekly initiation dialysis practiced in the 
context of an incremental programme, with dialysis duration and frequency subsequently 
adjusted according to the level of regularly monitored renal function. 
 
There were baseline differences between the groups. There were proportionately more women 
in the 2XHD group. The group was slightly but significantly younger and had a lower mean body 
weight. The 2XHD group also had a lower comorbid burden especially with respect to the 
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prevalence of diabetes and peripheral vascular disease. Though we controlled for these factors 
in the survival analysis and mixed effects model analyzing decline of KRU, there remains a 
significant likelihood that other potentially important confounders have not been accounted for 
in this analysis. In our survival analysis, baseline KRU was not a predictor of survival but this is 
only because our analysis excluded patients with baseline KRU<3ml/min which will have 
reduced variance.  
 
The mechanisms underlying the apparent benefits of initiating dialysis on a 2XHD schedule 
remain to be elucidated. However it is tempting to speculate that reduced exposure to aspects 
of the dialysis process, including ultrafiltration, probing for dry weight, exposure to the dialysis 
membrane and extracorporeal circulation, may play a role. Such factors may also be important 
contributants to some of the other benefits described above. In previous studies preservation 
of kidney function has also been associated with improved anaemia management, reduced 
ultrafiltration volumes, and improved survival [6, 10, 16]. There may also be a direct effect of 
reduced ultrafiltration on limiting dialysis-induced myocardial damage [26]. It is not possible to 
exclude other factors contributing to these findings such as confounding by selection. Since the 
frequency of treatment was not randomly allocated it may be that rate of decline of renal 
function was a factor in decisions to initiate and maintain prescriptions in relation to treatment 
frequency. In addition as mentioned above, survival may be influenced by other factors which 
have not been accounted for. The similarity between small solute clearances in the two groups 
suggest dialysis adequacy was not a factor in the survival findings, though the higher renal 
clearances in the 2XHD group might suggest that there may have been better middle molecule 
clearances in this group. Unfortunately, we do not have data to compare blood pressure control 
between groups.  
 
The survival benefit seemed to be limited to women and patients with lower body weight, 
suggesting that RKF provides a relatively greater contribution to total clearance of uraemic 
toxins in women and smaller individuals, and reinforcing the notion that RKF contributes much 
more to overall wellbeing in dialysis patients than just enhanced small solute clearance. It is 
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also worthy of comment that this benefit occurs in spite of the relatively higher generation per 
unit body mass of metabolic waste products in women and smaller individuals [27, 28].  
 
There are some limitations to our study. The study was retrospective and observational. Dialysis 
frequency was not assigned randomly. There was certainly selection bias evidenced by the 
baseline differences between 2XHD and 3XHD groups with reference to age, gender 
distribution, body weight and comorbidity. We attempted to mitigate the effects of the 
differences on survival but cannot exclude the potential role of other, unaccounted for, 
confounders. For instance we were unable to control for late referral. Lead-time bias is often a 
problem in such studies. The similarity between levels of RKF in the two groups suggests that 
this may not be a major factor in this study. However it is possible that the trajectory of RKF 
decline was different in the two groups in the pre-dialysis setting and that this has influenced 
dialysis prescription.  Perhaps an argument against this is the lack of major difference between 
the groups with respect to primary renal disease.  We used European Best Practice Guidance 
method of assessing KRU using average of pre- and post-dialysis urea clearance corrected for 
rebound but this method may introduce some slight bias, though this is unlikely to have had 
substantial impact on between-group comparisons as we used the same method for all 
patients[29]. Small bias may also exist due to not performing formal urea kinetic modelling to 
estimating time average urea concentration for calculating KRU, and this may have caused 
slightly higher KRU for patients on twice weekly dialysis, though the effect is small[30]. 
 
Our findings suggest that twice weekly dialysis initiation as part of an incremental dialysis 
programme with regular monthly monitoring of residual kidney function is safe and may reduce 
loss of RKF and improve outcomes for some patients. Evidence is accumulating suggesting that 
applying a single fixed dialysis regime at initiation, without taking account of RKF, may be 
potentially harmful for some individuals. This has led to recent calls for randomised controlled 
trials comparing an incremental approach including twice weekly initiation with conventional 
thrice-weekly regimes, in patients with adequate RKF [8, 24, 31-33]. This study adds further 
weight to these calls.  
14 
 
 
Conflicts of Interest Statement 
The results presented in this paper have not been published previously, either in whole or in 
part, except in abstract format. No authors declare any conflict of interest.  
15 
 
 
Table 1 
Baseline characteristics of twice-weekly (2XHD) and three-times (3XHD) groups. KRU = urea 
clearance.  
 
 
 
 
  
 2XHD group 3XHD group p-value 
N 154 411  
Age (years) 59 ± 15 62  ± 15 0.014 
Female (%) 34 27 0.004 
Baseline pre-dialysis weight (kg) 70  ± 16 80 ± 18 <0.001 
KRU (ml/min) 5.3 ± 2.4 5.1 ± 2.8 0.507 
Haemoglobin (g/l) 98 ± 16 99 ± 16  0.509 
Primary Renal Disease    
   Diabetic Nephropathy (%) 19 24  
   Chronic Glomerulonephritis (%) 14 13  
   Chronic Interstitial Disease (%) 8 4  
   Polycystic Kidney Disease (%) 10 5 0.08 
   Hypertension/Ischaemia (%) 8 13  
   Other diseases (%) 20 15  
   Unknown (%) 21 25  
Comorbidity at initiation     
   Diabetes (%) 25 34 0.04 
   Cardiac Disease (%) 21 29 0.06 
   Peripheral Vascular disease (%) 13 23 0.008 
    Malignancy (%) 10 13 0.293 
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Table 2 
Mixed effects model for prediction of KRU showing parameters included in the model. The 
model allowed for within-individual variation in baseline KRU (random intercept) and rate of 
change in KRU allowed to vary over time. Modelling was fitted using restricted cubic splines and 
knots at the 12 and 24 month time points. Use of splines resulted in three time parameters and 
three group-time interaction parameters. 
Parameter Estimate SE p-value 
Intercept 3.2196 0.3881 <0.001 
HD group (2XHD) 0.7018 0.1785 <0.001 
Time_1 -0.2577 0.0128 <0.001 
Time_2 1.1042 0.0946 <0.001 
Time_3 -2.2929 0.2241 <0.001 
HD group*time_1 0.1588 0.0248 <0.001 
HD group*time_2 -1.0675 0.183 <0.001 
HD group*time_3 2.3773 0.4333 <0.001 
Sex 0.3674 0.1475 0.013 
Age -0.002 0.0043 0.635 
Weight 0.0199 0.0034 <0.001 
Diabetes -0.0556 0.1346 0.68 
Cardiac disease -0.3836 0.1466 0.009 
PVD 0.0901 0.1612 0.576 
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Table 3 
Mixed effects model summaries for outcome differences comparing 2XHD and 3XHD groups 
Outcome Intercept 
2XHD 
Group 
Time 
HD 
Group*Time 
(interaction) 
Time^2 
Random Effects 
Residual 
SD SD 
Time 
SD 
Intercept 
Potassium 
Coefficient 4.66 0.01 0.02 -0.001 0.000 0.01 0.44 0.589 
p-value <0.001 0.925 <0.001 0.676 <0.001       
Phosphate 
Coefficient 1.82 -0.03 -0.002 0.001 - -  0.246 0.503 
p-value <0.001 0.372 0.007 0.471 -       
Haemoglobin 
Coefficient 101.90 -0.55 0.70 0.02 -0.01 0.22 10.00 12.94 
p-value <0.001 0.647 <0.001 0.586 <0.001       
Erythropoietin 
dose 
Coefficient 7230 -1435 99 -45 - 126 2974 3478 
p-value <0.001 <0.001 <0.001 0.018 -       
Erythropoietin 
Resistance 
Index 
Coefficient 0.573 -0.194 0.029 -0.002 0.000 0.016 0.387 0.526 
p-value <0.001 <0.001 <0.001 0.359 <0.001       
Ultrafiltration 
volue 
Coefficient 1478 -568 9 4 - 21 1118 788 
p-value <0.001 <0.001 <0.001 0.182 -       
Total 
Standard Kt/V 
Coefficient 2.345 0.011 -0.001 -0.002 - 0.026 0.358 0.574 
 p-value <0.001 0.851 0.525 0.676 -    
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Table 4. Cox proportional hazards models for mortality associated with twice-weekly versus 
thrice weekly treatments (Full model). The model was then applied separately for men and for 
women, and for those whose body weight was less than and greater than the median. Baseline 
KRU = best estimate of residual urea clearance in the three months following dialysis initiation 
 
 B SE Wald P-value. 
Hazard 
Ratio 
95.0% CI for Hazard 
Ratio 
Full model       
Age at Baseline (years) .034 .005 44.551 .000 1.035 1.024 - 1.045 
Female gender -.162 .132 1.497 .221 .851 0.657 - 1.102 
Weight at baseline (kg) -.006 .004 2.322 .128 .995 0.987 - 1.002 
Diabetes .297 .117 6.480 .011 1.346 1.071 - 1.692 
Cardiac Disease -.042 .121 .119 .730 .959 0.757 - 1.215 
Peripheral Vascular Disease .379 .128 8.740 .003 1.461 1.136 - 1.879 
Malignancy .665 .153 18.948 .000 1.944 1.441 - 2.622 
Baseline KRU (ml/min)* -.008 .030 .068 .794 .992 0.935 - 1.053 
Twice- weekly HD -.281 .139 4.073 .044 .755 0.574 - 0.992 
Gender restricted analyses – same covariates 
In women: Twice-weekly HD -.580 .280 4.295 0.038 .560 0.323 - 0.969 
In men: Twice-weekly HD -.148 .163 .828 0.363 .862 0.627 – 1.186 
Weight restricted analyses –same covariates 
Weight < median: Twice-weekly HD -.494 .179 7.600 0.006 .610 0.430 – 0.867 
Weight > median: Twice-weekly HD -.137 .232 .349 0.555 1.147 0.723 – 1.806 
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Figure 1: Decline of residual urea clearance (KRU) over five years in patients with KRU of 3 
ml/min or more, initiated on twice-weekly (2XHD) and thrice-weekly (3XHD) haemodialysis.  
 
Figure 2. Effect of 2XHD compared to 3XHD on KRU from mixed effect model. There is 
increasing difference between groups to 12 months. From 12 to 24 months the difference in 
KRU between groups decreases as the 3XHD group levels out while the 2XHD groups’s KRU 
continues to decrease.  
Figure 3. Mixed effects model for predicting KRU: performance of the model comparing 
observed and fitted data. 
Figure 4. Differences in haemoglobin levels, erythropoietin dose and Erythropoietin Resistance 
Index over five years following initiation of dialysis in patients on 2XHD (light grey) and 3XHD 
(dark grey). 
Figure 5. Total Standard Kt/V with renal and dialysis components  over five years following 
initiation of dialysis in 2XHD and 3XHD groups (Light grey2XHD, dark grey 3XHD). 
Figure 6. Ultrafiltration volume over five years following initiation of dialysis in 2XHD and 3XHD 
groups. 
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